The study found that the price tag for the second-generation Bruton tyrosine kinase inhibitor would need to be reduced by 30% ...

In the years since targeted treatments for CLL were introduced, their use in the second line has increased, but chemotherapy ...

Background Studies examining the relationship between serological status (rheumatoid factor and/or anticitrullinated antibody) and rituximab treatment outcome in rheumatoid arthritis (RA) have been ...

The introduction of biologic agents, especially rituximab (RTX), a chimeric monoclonal antibody targeting CD20+ B cells, has revolutionized the treatment landscape. This review synthesized the current ...

A study found that switching from rituximab to biosimilar CT-P10 is safe and effective for patients with systemic lupus ...

Background: Rituximab (RTX) is a monoclonal antibody that has been increasingly used in the treatment of myasthenia gravis (MG). In most studies, the therapeutic protocol of RTX has been similar to ...

A 3-year follow-up of patients with refractory/relapsed indolent non-Hodgkin (NHL) treated with a combination of magrolimab and rituximab showed no new treatment-emergent adverse events ...

A phase 1b trial showed promising results among patients with relapsed or refractory chronic lymphocytic leukemia.

Treatment options for PPMS are limited and often fail to slow disability progression. Both Ocrevus and rituximab are designed to promote the death of B-cells, the immune cells that produce the ...

She was admitted to hospital as an emergency with prolonged and painful extensor spasms affecting the neck and back, arms, and legs. The disease had progressed despite a favourable initial response to ...

Researchers found that the most common first-line treatment regimen was fludarabine, cyclophosphamide, and rituximab. The use of targeted therapies for chronic lymphocytic leukemia (CLL ...